StockData
Vaxart, Inc. logo

Vaxart, Inc. (VXRT) stock

VXRTOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/30
$0.48+0.02 (+5.04%)

Close on Oct 19, 2026Market cap $115.15MP/E 3.2Yield –

Vaxart net income

Net income is the profit left for shareholders after every expense, interest and tax.

Vaxart's net income for the twelve months ending Jun 30, 2026 was $38.59M. For fiscal 2025 it was $16.33M. The highest annual figure on record is $16.33M in fiscal 2025.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$16.33M–
FY2024Dec 31, 2024-$66.95M–
FY2023Dec 31, 2023-$82.47M–
FY2022Dec 31, 2022-$107.76M–
FY2021Dec 31, 2021-$70.47M–
FY2020Dec 31, 2020-$32.22M–
FY2019Dec 31, 2019-$18.65M–
FY2018Dec 31, 2018-$18.01M–
FY2016Jun 30, 2016-$25.40M–
FY2015Jun 30, 2015-$19.10M–
FY2014Jun 30, 2014-$11.00M–
FY2013Jun 30, 2013-$8.90M–
FY2012Jun 30, 2012-$19.20M–
FY2009Dec 26, 2009-$18.73M–

Quarterly net income

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q2 FY2026CQ2 2026Jun 30, 2026-$13.49M–
Q1 FY2026CQ1 2026Mar 31, 2026$5.18M–
Q4 FY2025CQ4 2025Dec 31, 2025$55.05M–
Q3 FY2025CQ3 2025Sep 30, 2025-$8.14M–
Q2 FY2025CQ2 2025Jun 30, 2025-$14.99M–
Q1 FY2025CQ1 2025Mar 31, 2025-$15.59M–
Q4 FY2024CQ4 2024Dec 31, 2024-$11.99M–
Q3 FY2024CQ3 2024Sep 30, 2024-$14.08M–
Q2 FY2024CQ2 2024Jun 30, 2024-$16.47M–
Q1 FY2024CQ1 2024Mar 31, 2024-$24.42M–
Q4 FY2023CQ4 2023Dec 31, 2023-$17.38M–
Q3 FY2023CQ3 2023Sep 30, 2023-$17.40M–
Q2 FY2023CQ2 2023Jun 30, 2023-$22.55M–
Q1 FY2023CQ1 2023Mar 31, 2023-$25.14M–
Q4 FY2022CQ4 2022Dec 31, 2022-$23.92M–
Q3 FY2022CQ3 2022Sep 30, 2022-$29.31M–
Q2 FY2022CQ2 2022Jun 30, 2022-$29.43M–
Q1 FY2022CQ1 2022Mar 31, 2022-$25.10M–
Q4 FY2021CQ4 2021Dec 31, 2021-$20.76M–
Q3 FY2021CQ3 2021Sep 30, 2021-$17.58M–
Q2 FY2021CQ2 2021Jun 30, 2021-$16.12M–
Q1 FY2021CQ1 2021Mar 31, 2021-$16.01M–
Q4 FY2020CQ4 2020Dec 31, 2020-$13.86M–
Q3 FY2020CQ3 2020Sep 30, 2020-$8.09M–
Q2 FY2020CQ2 2020Jun 30, 2020-$8.98M–
Q1 FY2020CQ1 2020Mar 31, 2020-$1.30M–
Q4 FY2019CQ4 2019Dec 31, 2019-$6.41M–
Q3 FY2019CQ3 2019Sep 30, 2019-$5.26M–
Q2 FY2019CQ2 2019Jun 30, 2019-$5.64M–
Q1 FY2019CQ1 2019Mar 31, 2019-$1.34M-157.9%
Q4 FY2018CQ4 2018Dec 31, 2018-$4.90M–
Q3 FY2018CQ3 2018Sep 30, 2018-$6.55M–
Q2 FY2018CQ2 2018Jun 30, 2018-$8.87M–
Q1 FY2018CQ1 2018Mar 31, 2018$2.31M–
Q4 FY2016CQ2 2016Jun 30, 2016-$7.10M–
Q3 FY2016CQ1 2016Mar 31, 2016-$5.20M-533.3%
Q2 FY2016CQ4 2015Dec 31, 2015-$6.50M–
Q1 FY2016CQ3 2015Sep 30, 2015-$6.60M–
Q4 FY2015CQ2 2015Jun 30, 2015-$19.90M–
Q3 FY2015CQ1 2015Mar 31, 2015$1.20M–

More Vaxart figures

See a number that looks wrong?